Stockscreener 앱 받기
146.42
0.71%
-0.94
전일 마감가:
$147.36
열려 있는:
$146.07
하루 거래량:
144.93K
시가총액:
$18.50B
수익:
$1.83B
순이익/손실:
$-440.24M
주가수익비율:
-35.37
EPS:
-4.14
순현금흐름:
$41.95M
1주 성능:
+0.17%
1개월 성능:
-2.09%
6개월 성능:
-3.36%
1년 성능:
-26.55%
1일 변동 폭
$145.42
$148.05
52주 변동 폭
$141.97
$218.88
Alnylam Pharmaceuticals Inc Stock (ALNY) Company Profile
명칭
Alnylam Pharmaceuticals Inc
전화
617-551-8200
주소
300 Third Street, 3rd Floor, Cambridge, MA
Alnylam Pharmaceuticals Inc Stock (ALNY) Upgrades & Downgrades
| 날짜 | 액션 | 분석자 | 등급 변경 |
|---|---|---|---|
| 2024-02-16 | 다운그레이드 | Goldman | Buy → Neutral |
| 2024-02-15 | 개시 | Wolfe Research | Peer Perform |
| 2023-12-08 | 개시 | Wells Fargo | Equal Weight |
| 2023-10-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2023-09-29 | 개시 | Raymond James | Outperform |
| 2023-05-05 | 업그레이드 | BMO Capital Markets | Market Perform → Outperform |
| 2023-04-26 | 개시 | SMBC Nikko | Neutral |
| 2023-03-21 | 개시 | Bernstein | Outperform |
| 2023-01-18 | 개시 | Canaccord Genuity | Buy |
| 2022-09-09 | 재개 | Morgan Stanley | Equal-Weight |
| 2022-07-13 | 개시 | Cantor Fitzgerald | Neutral |
| 2022-06-27 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2022-06-07 | 개시 | William Blair | Outperform |
| 2022-04-25 | 다운그레이드 | Morgan Stanley | Overweight → Equal-Weight |
| 2022-03-01 | 개시 | Citigroup | Buy |
| 2022-02-03 | 업그레이드 | Guggenheim | Neutral → Buy |
| 2022-01-03 | 업그레이드 | Piper Sandler | Neutral → Overweight |
| 2021-11-22 | 업그레이드 | Goldman | Neutral → Buy |
| 2021-11-22 | 업그레이드 | RBC Capital Mkts | Sector Perform → Outperform |
| 2021-11-01 | 업그레이드 | Oppenheimer | Perform → Outperform |
| 2021-10-04 | 업그레이드 | UBS | Neutral → Buy |
| 2021-08-04 | 다운그레이드 | Piper Sandler | Overweight → Neutral |
| 2021-02-22 | 다운그레이드 | Guggenheim | Buy → Neutral |
| 2021-02-12 | 다운그레이드 | Citigroup | Buy → Neutral |
| 2021-02-12 | 재확인 | H.C. Wainwright | Buy |
| 2021-01-25 | 다운그레이드 | BMO Capital Markets | Outperform → Market Perform |
| 2020-09-30 | 재개 | Berenberg | Hold |
| 2020-09-08 | 개시 | Citigroup | Buy |
| 2020-08-11 | 다운그레이드 | Oppenheimer | Outperform → Perform |
| 2020-05-13 | 개시 | RBC Capital Mkts | Sector Perform |
| 2020-05-07 | 다운그레이드 | JP Morgan | Overweight → Neutral |
| 2020-04-24 | 재개 | Evercore ISI | Outperform |
| 2020-03-19 | 개시 | Berenberg | Buy |
| 2019-12-19 | 재확인 | Chardan Capital Markets | Buy |
| 2019-11-20 | 개시 | Oppenheimer | Outperform |
| 2019-11-13 | 개시 | BofA/Merrill | Buy |
| 2019-05-23 | 재개 | Goldman | Neutral |
| 2019-04-12 | 개시 | Evercore ISI | Outperform |
| 2019-03-06 | 업그레이드 | Evercore ISI | In-line → Outperform |
| 2019-03-05 | 업그레이드 | Morgan Stanley | Equal-Weight → Overweight |
| 2019-01-23 | 개시 | UBS | Neutral |
| 2018-10-01 | 개시 | Cantor Fitzgerald | Overweight |
| 2018-08-13 | 재확인 | Stifel | Buy |
| 2018-08-07 | 업그레이드 | Stifel | Hold → Buy |
| 2018-05-04 | 재확인 | Stifel | Hold |
| 2018-03-28 | 개시 | Evercore ISI | In-line |
모두보기
Alnylam Pharmaceuticals Inc 주식(ALNY)의 최신 뉴스
Gear Up for Alnylam (ALNY) Q1 Earnings: Wall Street Estimates for Key Metrics
Zacks Investment Research
Vertex (VRTX) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
What's in the Cards for Amgen (AMGN) This Earnings Season?
Zacks Investment Research
Ocugen (OCGN) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Zoetis (ZTS) to Report Q1 Earnings: What's in the Cards?
Zacks Investment Research
Alnylam Pharmaceuticals (ALNY) Expected to Beat Earnings Estimates: Can the Stock Move Higher?
Zacks Investment Research
Alnylam Pharmaceuticals Inc (ALNY) 재무 분석
Alnylam Pharmaceuticals Inc (ALNY) 매출 2024
ALNY은 2023-12-31 종료 분기에 대해 매출(지난 12개월)이 1.83B 달러로 보고했으며, 전년대비 +76.23% 상승했습니다.
Alnylam Pharmaceuticals Inc (ALNY) 순이익 2024
ALNY은 2023-12-31 종료 분기에 대해 순이익(지난 12개월)이 -440.24M 달러로 보고했으며, 전년대비 +61.08% 증가했습니다.
Alnylam Pharmaceuticals Inc (ALNY) 현금흐름 2024
2023-12-31 종료 분기에 ALNY은 현금흐름(지난 12개월)으로 41.95M 달러를 기록했으며, 전년 대비 +106.84% 증가했습니다.
Alnylam Pharmaceuticals Inc (ALNY) 주당 순이익 2024
ALNY이 보고한 2023-12-31 종료 분기의 주당 순이익(지난 12개월)은 -3.56달러이며, 전년 대비 +61.68% 성장했습니다.
Alnylam Pharmaceuticals Inc 주식 (ALNY) 내부자 거래
| 내부자 거래 | 관계 | 날짜 | 거래 | 비용 | #주식 | 가치 ($) | #주식 총계 |
|---|---|---|---|---|---|---|---|
| SHARP PHILLIP A | Director |
Feb 29 '24 |
Sale |
151.34 |
30,000 |
4,540,071 |
0 |
| Greenstreet Yvonne | Chief Executive Officer |
Feb 28 '24 |
Sale |
155.31 |
2,932 |
455,357 |
48,128 |
| Garg Pushkal | CMO & EVP Dev & Med Affairs |
Feb 28 '24 |
Sale |
155.30 |
574 |
89,145 |
8,666 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Feb 28 '24 |
Sale |
155.30 |
574 |
89,145 |
19,478 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Feb 28 '24 |
Sale |
155.30 |
501 |
77,805 |
5,236 |
| Franchini Indrani Lall | EVP, CLO & Secretary |
Feb 28 '24 |
Sale |
155.30 |
329 |
51,094 |
4,133 |
| Franchini Indrani Lall | EVP, CLO & Secretary |
Feb 27 '24 |
Option Exercise |
0.00 |
878 |
0 |
4,462 |
| Greenstreet Yvonne | Chief Executive Officer |
Feb 27 '24 |
Option Exercise |
0.00 |
5,921 |
0 |
51,060 |
| Tanguler Tolga | EVP, Chief Commercial Officer |
Feb 27 '24 |
Option Exercise |
0.00 |
1,667 |
0 |
5,737 |
| Poulton Jeffrey V. | EVP, Chief Financial Officer |
Feb 27 '24 |
Option Exercise |
0.00 |
1,908 |
0 |
20,052 |
2.28%
1.02%
자본화:
|
볼륨(24시간):